Impact of glucagon‐like peptide‐1 receptor agonism‐based therapies on limb outcomes in peripheral artery disease and type 2 diabetes: An updated systematic review and meta‐analysis
Diabetes, Obesity and Metabolism · 2026-03 · 28 (3) · 2075-2084
DOI: 10.1111/dom.70391 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Diabetes, Obesity and Metabolism, online erschienen am 22.12.2025. Verfasst von Deep Dutta und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology, CEDAR Superspeciality Healthcare, New Delhi, India. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Peripheral Arterial Disease, Glucagon-Like Peptide-1 Receptor Agonists, Hypoglycemic Agents. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 43 Literaturangaben.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Aims Glucagon‐like peptide‐1 receptor agonism (GLP1RA)‐based therapies (GLP1RA‐BTs) form the cornerstone for managing type 2 diabetes (T2D) and obesity. However, their impact on limb‐specific outcomes in peripheral artery disease (PAD) remains unclear. This systematic‐review and meta‐analysis evaluated the safety and efficacy of GLP1RA‐BTs on limb outcomes in PAD and T2D. Materials and methods Electronic databases were searched for studies involving GLP1RA‐BTs in PAD and/or T2D. Primary outcome was the major adverse limb events (MALEs). Secondary outcomes were all‐cause mortality, revascularization, amputation, major adverse cardiovascular events (MACE), cardiovascular mortality, myocardial infarction (MI), stroke, hospitalization for heart‐failure (HHF), and amputations. Analyses were performed separately for studies exclusively enrolling patients with PAD (PAD cohort) and for those in broader T2D populations reporting limb outcomes but not limited to PAD, in which PAD comprised
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Endocrinology, CEDAR Superspeciality Healthcare, New Delhi, India.
- Department of Cardiology, Himachal Heart Institute, Mandi, India.
- Department of Endocrinology, Mymensingh Medical College, Mymensingh, Bangladesh.
- Translational Research and Data Science Consultant, USA.
- Department of Rheumatology, CEDAR Superspeciality Healthcare, New Delhi, India.
- Mount Sinai Morningside, Icahn School of Medicine at Mount Sinai, New York, USA.
ORCID-Profile: Deep Dutta, Kunal Mahajan, Abul Bashar Mohammad Kamrul-Hasan, Nitin Mahajan, Shekhar Vohra
Zitieren
APA
Dutta, D., Mahajan, K., Kamrul-Hasan, A. B. M., Mahajan, N., Sharma, M., & Vohra, S. (2026). Impact of glucagon‐like peptide‐1 receptor agonism‐based therapies on limb outcomes in peripheral artery disease and type 2 diabetes: An updated systematic review and meta‐analysis. Diabetes, Obesity and Metabolism, 28(3), 2075-2084. https://doi.org/10.1111/dom.70391
Vancouver
Dutta D, Mahajan K, Kamrul-Hasan ABM, Mahajan N, Sharma M, Vohra S. Impact of glucagon‐like peptide‐1 receptor agonism‐based therapies on limb outcomes in peripheral artery disease and type 2 diabetes: An updated systematic review and meta‐analysis. Diabetes, Obesity and Metabolism. 2026;28(3):2075-2084. doi:10.1111/dom.70391
BibTeX
@article{Dutta2026,
author = {Dutta, Deep and Mahajan, Kunal and Kamrul-Hasan, Abul Bashar Mohammad and Mahajan, Nitin and Sharma, Meha and Vohra, Shekhar},
title = {Impact of glucagon‐like peptide‐1 receptor agonism‐based therapies on limb outcomes in peripheral artery disease and type 2 diabetes: An updated systematic review and meta‐analysis},
journal = {Diabetes, Obesity and Metabolism},
year = {2026},
volume = {28},
number = {3},
pages = {2075--2084},
doi = {10.1111/dom.70391}
}
EUVIMED